Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAINMAX in post-COVID asthenic syndrome
NCT05939622Phase 4Completed
- Sponsor
- Promomed
- Start
- May 2022
- Primary completion
- Dec 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Post COVID-19 Syndrome (PCS) comparing BRAINMAX with Placebo (2 arms). Primary endpoint: Changing patterns of brain activation using task fMRI with a cognitive paradigm at 10 days. Started May 2022; status: completed.
02
Drugs
Huperzine A
03
Conditions
Post COVID-19 Syndrome (PCS)
Beyond the preview
Go deeper on NCT05939622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05939622.